149 related articles for article (PubMed ID: 30229259)
1. Towards rational design of RAD51-targeting prodrugs: platinum
Zhang S; Yuan H; Guo Y; Wang K; Wang X; Guo Z
Chem Commun (Camb); 2018 Oct; 54(83):11717-11720. PubMed ID: 30229259
[TBL] [Abstract][Full Text] [Related]
2. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
4. A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.
Guo Y; Zhang S; Yuan H; Song D; Jin S; Guo Z; Wang X
Dalton Trans; 2019 Mar; 48(11):3571-3575. PubMed ID: 30793153
[TBL] [Abstract][Full Text] [Related]
5. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
6. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
8. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
9. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
Yang J; Liu W; Sui M; Tang J; Shen Y
Biomaterials; 2011 Dec; 32(34):9136-43. PubMed ID: 21889206
[TBL] [Abstract][Full Text] [Related]
10. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
Jayawardhana AMDS; Bhandari S; Kaspi-Kaneti AW; Kshetri M; Qiu Z; Cheline M; Shen H; Dunietz BD; Zheng YR
Dalton Trans; 2023 Aug; 52(31):10942-10950. PubMed ID: 37490033
[TBL] [Abstract][Full Text] [Related]
11. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
12. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
Najjar A; Rajabi N; Karaman R
Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
Jayawardhana AMDS; Stilgenbauer M; Datta P; Qiu Z; Mckenzie S; Wang H; Bowers D; Kurokawa M; Zheng YR
Chem Commun (Camb); 2020 Sep; 56(73):10706-10709. PubMed ID: 32789350
[TBL] [Abstract][Full Text] [Related]
14. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
15. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
16. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
Min Y; Li J; Liu F; Yeow EK; Xing B
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
[TBL] [Abstract][Full Text] [Related]
17. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
18. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
[TBL] [Abstract][Full Text] [Related]
19. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines.
Petruzzella E; Braude JP; Aldrich-Wright JR; Gandin V; Gibson D
Angew Chem Int Ed Engl; 2017 Sep; 56(38):11539-11544. PubMed ID: 28759160
[TBL] [Abstract][Full Text] [Related]
20. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
